Literature DB >> 20435688

S1P2 receptor-dependent Rho-kinase activation mediates vasoconstriction in the murine pulmonary circulation induced by sphingosine 1-phosphate.

William S Szczepaniak1, Bruce R Pitt, Bryan J McVerry.   

Abstract

Vasoactive properties of sphingosine 1-phosphate (S1P) have been demonstrated by many investigators to vary in systemic vascular beds. These variations appear to reflect differential S1P receptor expression in the vasculature of these tissues. Although S1P has been demonstrated to enhance endothelial barrier function, induce airway hyperresponsiveness, and modulate immune responses in the lung, the pulmonary vasomotor effects of S1P remain poorly defined. In the present study, we sought to define the vasoregulatory effects of S1P in the pulmonary vasculature and to elucidate the underlying mechanisms operative in effecting the response in the intact lung. S1P (10 microM) increased pulmonary vascular resistance (PVR) by 36% in the isolated perfused mouse lung. S1P-induced vasoconstriction was reduced by 64% by concomitant administration of the Rho-kinase inhibitor Y27632 (10 microM). Similarly, the S1P response was attenuated by >50% after S1P(2) receptor antagonism (JTE-013; 10 microM) and in S1P(2) receptor null mice. In contrast, S1P(3) receptor antagonism (VPC23019; 10 microM) had no effect on the contractile response to S1P. Furthermore, we confirmed the role of Rho-kinase as an important regulator of basal vasomotor tone in the isolated perfused mouse lung. These results suggest that S1P is capable of altering pulmonary vascular tone in vivo and may play an important role in the modulation of pulmonary vascular tone both in the normal lung and under pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435688      PMCID: PMC2904089          DOI: 10.1152/ajplung.00233.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  49 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Sphingosine 1-phosphate and control of vascular tone.

Authors:  Ana Paula V Dantas; Junsuke Igarashi; Thomas Michel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06       Impact factor: 4.733

Review 3.  Signaling and biological actions of sphingosine 1-phosphate.

Authors:  Timothy Hla
Journal:  Pharmacol Res       Date:  2003-05       Impact factor: 7.658

4.  RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.

Authors:  Christophe Guilluy; Saadia Eddahibi; Christian Agard; Christophe Guignabert; Mohamed Izikki; Ly Tu; Laurent Savale; Marc Humbert; Elie Fadel; Serge Adnot; Gervaise Loirand; Pierre Pacaud
Journal:  Am J Respir Crit Care Med       Date:  2009-03-19       Impact factor: 21.405

5.  Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.

Authors:  Khalil J Diab; Jeremy J Adamowicz; Krzysztof Kamocki; Natalia I Rush; Jana Garrison; Yuan Gu; Kelly S Schweitzer; Anastasia Skobeleva; Gangaraju Rajashekhar; Walter C Hubbard; Evgeny V Berdyshev; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2009-12-03       Impact factor: 21.405

6.  Sphingosine-1-phosphate receptor-2 regulates expression of smooth muscle alpha-actin after arterial injury.

Authors:  Allison D Grabski; Takuya Shimizu; Jessie Deou; William M Mahoney; Michael A Reidy; Guenter Daum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-16       Impact factor: 8.311

7.  Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction.

Authors:  Frederic Coussin; Roderick H Scott; Alan Wise; Graeme F Nixon
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

8.  S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate.

Authors:  Salvatore Salomone; Shin-ichi Yoshimura; Uwe Reuter; Melissa Foley; Sunu S Thomas; Michael A Moskowitz; Christian Waeber
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

9.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

10.  Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse.

Authors:  Fiorentina Roviezzo; Bruno D'Agostino; Vincenzo Brancaleone; Luana De Gruttola; Mariarosaria Bucci; Gianfranco De Dominicis; Donatella Orlotti; Elena D'Aiuto; Raffaele De Palma; Francesco Rossi; Raffaella Sorrentino; Giuseppe Cirino
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-25       Impact factor: 6.914

View more
  24 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient.

Authors:  Keisuke Yanagida; Timothy Hla
Journal:  Annu Rev Physiol       Date:  2016-10-21       Impact factor: 19.318

3.  CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction.

Authors:  Christoph Tabeling; Hanpo Yu; Liming Wang; Hannes Ranke; Neil M Goldenberg; Diana Zabini; Elena Noe; Adrienn Krauszman; Birgitt Gutbier; Jun Yin; Michael Schaefer; Christoph Arenz; Andreas C Hocke; Norbert Suttorp; Richard L Proia; Martin Witzenrath; Wolfgang M Kuebler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-17       Impact factor: 11.205

Review 4.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

5.  The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.

Authors:  Jiwang Chen; Haiyang Tang; Justin R Sysol; Liliana Moreno-Vinasco; Krystyna M Shioura; Tianji Chen; Irina Gorshkova; Lichun Wang; Long Shuang Huang; Peter V Usatyuk; Saad Sammani; Guofei Zhou; J Usha Raj; Joe G N Garcia; Evgeny Berdyshev; Jason X-J Yuan; Viswanathan Natarajan; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

Review 6.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 7.  Lysophospholipids and their receptors in the central nervous system.

Authors:  Ji Woong Choi; Jerold Chun
Journal:  Biochim Biophys Acta       Date:  2012-07-31

Review 8.  Sphingolipid signaling in metabolic disorders.

Authors:  Timothy Hla; Andrew J Dannenberg
Journal:  Cell Metab       Date:  2012-09-13       Impact factor: 27.287

9.  Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension.

Authors:  Salina Gairhe; Sachindra R Joshi; Mrigendra M Bastola; Jared M McLendon; Masahiko Oka; Karen A Fagan; Ivan F McMurtry
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

10.  Upregulation of S1P1 and Rac1 receptors in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia.

Authors:  Julia Zimmer; Toshiaki Takahashi; Johannes W Duess; Alejandro D Hofmann; Prem Puri
Journal:  Pediatr Surg Int       Date:  2015-11-05       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.